Universidad de Navarra
Organización
University of Calgary
Calgary, CanadáPublicaciones en colaboración con investigadores/as de University of Calgary (58)
2025
-
Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network analyses
European Neuropsychopharmacology, Vol. 90, pp. 1-15
2024
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457
-
Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study
Psychiatry Research, Vol. 342
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)
Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516
-
Validation of the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) questionnaire for adults
Journal of Affective Disorders, Vol. 326, pp. 249-261
2022
-
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
Critical Care, Vol. 26, Núm. 1
-
Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A)
Journal of Affective Disorders, Vol. 299, pp. 367-376
-
Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis
Journal of Hepatology, Vol. 77, Núm. 1, pp. 98-107
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
-
The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
Journal of Affective Disorders, Vol. 299, pp. 393-407
2021
-
Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET
Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820
-
Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C
Journal of Clinical Endocrinology and Metabolism, Vol. 106, Núm. 2, pp. E660-E674
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
The Lancet, Vol. 398, Núm. 10315, pp. 1984-1996
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118